Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
2.93
Nov 06 • 3:59 PM ET Dollar change-0.13 Percentage change(-4.25%)
Aftermarket Close
2.87
Aftermarket • 7:30 PM ET Dollar change-0.06 Percentage change(-2.05%)
Nov 05, 10:52 AMApyx Medical beats Q3 estimates with $14M revenue, narrower $0.04 loss, turns adjusted and trailing 12-month EBITDA positive, reaffirms 2026 outlook
Index
-
Market Cap
123.42M
Enterprise Value
137.80M
Income
-8.44M
Sales
59.57M
Book/sh
0.23
Cash/sh
0.61
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
205
IPO
Feb 22, 1999
P/E
-
Forward P/E
-
PEG
-
P/S
2.07
P/B
12.82
P/C
4.79
P/FCF
-
EV/EBITDA
-
EV/Sales
2.31
Quick Ratio
3.85
Current Ratio
4.95
Debt/Eq
4.13
LT Debt/Eq
4.08
Option/Short
Yes / Yes
EPS (ttm)
-0.19
EPS next Y
-0.20
EPS next Q
-0.04
EPS this Y
19.77%
EPS next Y
8.13%
EPS next 5Y
31.59%
EPS past 3/5Y
25.94% 4.74%
Sales past 3/5Y
5.89% 13.78%
EPS Y/Y TTM
46.90%
Sales Y/Y TTM
24.35%
EPS Q/Q
16.84%
Sales Q/Q
8.95%
Insider Own
13.56%
Insider Trans
0.00%
Inst Own
53.39%
Inst Trans
6.78%
ROA
-14.17%
ROE
-108.99%
ROIC
-17.25%
Gross Margin
38.45%
Oper. Margin
-5.50%
Profit Margin
-14.16%
SMA20
13.30%
SMA50
7.01%
SMA200
-17.96%
Trades
Shs Outstand
42.12M
Shs Float
36.41M
52W High
5.08 -42.32%
52W Low
2.25 30.22%
Volatility
11.48% 7.50%
ATR (14)
0.21
RSI (14)
60.71
Beta
1.39
Rel Volume
1.28
Avg Volume
156.92K
Volume
201,263
Perf Week
12.69%
Perf Month
24.15%
Perf Quarter
-15.32%
Perf Half Y
-20.16%
Perf YTD
-16.29%
Perf Year
-12.54%
Perf 3Y
14.90%
Perf 5Y
-80.63%
Perf 10Y
-41.40%
Prev Close
3.06
Price
2.93
Change %
-4.25%
Consensus
Strong Buy
Avg. Price Target
$6.50
Implied Upside
+121.8%
Analysts8incl. previous ratings
Rating Distribution8 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 29, 2026Initiated
MMaxim Group
Buy$6+104.8%
Jul 13, 2026Initiated
HH.C. Wainwright
Buy$7+138.9%
Mar 11, 2026Upgrade
BBTIG Research
Neutral → Buy$6+104.8%
Dec 16, 2025Initiated
RRoth Capital
Buy$6+104.8%
Nov 14, 2025Upgrade
CCitizens JMP
Mkt Perform → Mkt Outperform
Nov 12, 2025Upgrade
CCitizens JMP
Mkt Perform → Mkt Outperform$8+173.0%
Oct 17, 2024Initiated
BBTIG Research
Neutral
Jul 14, 2023Initiated
SStephens
Overweight$8+173.0%
May 20, 2022Initiated
LLake Street
Buy$12+309.6%
Apr 02, 2019Reiterated
DDougherty & Company
Buy$12 → $9+207.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Waldman LawrenceDirectorJun 30 '26Option Exercise1.8812,00022,56017,338Jul 02 05:00 PM
Roman Shawn DavidChief Operating OfficerJun 15 '26Option Exercise3.2315,00048,45015,000Jun 17 05:15 PM
CITRONOWICZ MOSHESenior Vice PresidentMar 15 '26Option Exercise1.8037,00066,600493,504Mar 17 06:27 PM
Roman Shawn DavidChief Operating OfficerJan 27 '26Option Exercise1.8012,00021,60012,000Jan 29 05:21 PM
Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used by the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Surgical Aesthetics and Original Equipment Manufacturer (OEM). The Surgical Aesthetics segment consists of the Helium Plasma Technology lines, which include Renuvion and J-Plasma. The OEM segment focuses on designing, development, and manufacturing electrosurgical equipment and medical devices by producing generators, medical devices and related accessories. The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
PresidentMr. Charles D. Goodwin II
CFOMr. Matthew C. Hill CPA
Chief Operating OfficerMr. Shawn D. Roman
Senior Vice PresidentMr. Moshe Citronowicz
Chief of ConfidenceMs. Dolores Catania